Novel Nanomedicine-Based Therapeutic Approach For Treatment of Cancer Cachexia
治疗癌症恶病质的新型纳米医学治疗方法
基本信息
- 批准号:10400155
- 负责人:
- 金额:$ 44.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:ActivinsAddressAffectAttenuatedBehaviorBehavioralBindingBlood CirculationCachexiaCancer ModelCancer PatientCause of DeathCellsCessation of lifeClinical TrialsDataDifferentiation and GrowthDiseaseDrug Delivery SystemsExhibitsFatty acid glycerol estersFollistatinGDF8 geneGene DeliveryGlycoproteinsGoalsHealthHepatocyteHormone secretionHormonesHumanImpairmentInflammationInjectionsIntravenousKupffer CellsLiverLungMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMediatingMedicalMessenger RNAMetabolicModelingMusMuscular AtrophyMyoblastsNutritional SupportPancreasPancreatic Ductal AdenocarcinomaPatientsPersonsPharmacologyPlayPolymersPostoperative ComplicationsProductionProteinsQuality of lifeResearchResearch PersonnelRoleRouteSerumSkeletal MuscleStomachSubcutaneous InjectionsSyndromeSystemTechnologyTestingTherapeuticThinnessToxic effectTreatment EfficacyTreatment outcomeWild Type Mouseactivin Aantagonistattributable mortalitybasecancer cachexiacancer therapychemotherapydesigneffective therapyefficacious treatmentgene therapyimprovedintravenous administrationlean body massmorphogensmouse modelmultidisciplinarymuscle formnanomedicinenanoparticlenanotechnology platformnovelnovel therapeuticsoverexpressionpalliationpancreatic ductal adenocarcinoma modelpatient populationpreclinical studypreservationpreventreceptorskeletal muscle wastingskeletal preservationsubcutaneoussystemic inflammatory responsetranslational potentialtranslational therapeuticstumor
项目摘要
Project Summary
Cachexia is a debilitating syndrome that occurs in numerous diseases including cancer and is characterized by
a significant loss of skeletal muscle mass (with or without fat loss) that cannot be reversed by nutritional support.
It most commonly occurs in gastric (85% of patients), pancreatic (83%) and lung (61%) cancers and up to 30%
of deaths in these patient populations are attributable to cachexia alone. The numerous clinical trials confirmed
that wasting of skeletal muscle mass is the hallmark of cachexia and it is responsible for shorter survival, poor
treatment outcomes, increased toxicity to chemotherapy, post-operative complications, and physical impairment.
Despite all efforts, there are currently no effective therapies to prevent muscle wasting in cachectic patients.
A multidisciplinary team of investigators with complementary expertise in drug delivery, gene therapy, and cancer
cachexia will develop an effective treatment for cachexia-associated muscle wasting. It will be based on
polymeric nanoparticles specifically designed to deliver follistatin messenger RNA (mRNA) to the liver cells after
systemic administration. The delivered mRNA will direct the cellular machinery of the liver cells to produce
follistatin, a secreted glycoprotein that is capable of increasing lean muscle mass through inhibition of myostatin
and Activin A. The last two are growth differentiation factors whose serum concentrations are increased in
cachectic states, and they play a critical role in negatively regulating muscle mass.
The research team has already developed mRNA-loaded nanoplatform that is non-toxic and elevates serum
levels of follistatin protein within 8 h after subcutaneous injection. Wild-type mice that were treated with the
nanoplatform exhibited significant increases in lean body mass. To further advance this technology, the goals
are: (i) to enhance the delivery of the already developed nanoparticles to the liver, (ii) to evaluate delivery
efficiency of the nanoparticles in mice with the humanized liver, and (iii) to validate therapeutic efficacy of the
nanoparticles in novel murine pancreatic ductal adenocarcinoma (PDAC) and lung cancer models that exhibit all
the hallmark features of human cachexia. These goals will be addressed with the following Specific Aims: 1
Evaluate the efficiency of mRNA-loaded nanoparticles following intravenous administration. 2. Test nanoplatform
in mice with the humanized liver. 3. Determine whether nanoparticle-mediated delivery of follistatin mRNA
attenuates cachexia in mouse models of PDAC and lung cancer.
At the completion of this project, the research team will produce strong evidence that the proposed therapy will
preserve muscle mass and attenuate other features of cachexia in mice with pancreatic and lung cancers. The
long-term impact of this project is the successful application of the novel treatment in medical practice to
sufficiently limit death and suffering from various cancers including lung and pancreatic cancers.
项目摘要
恶病质是一种衰弱综合征,发生在包括癌症在内的许多疾病中,其特征在于:
骨骼肌质量的显著损失(有或没有脂肪损失),不能通过营养支持逆转。
最常见于胃癌(85%的患者)、胰腺癌(83%)和肺癌(61%),
这些患者人群的死亡仅归因于恶病质。大量的临床试验证实
骨骼肌质量的消耗是恶病质的标志,
治疗结果、化疗毒性增加、术后并发症和身体损伤。
尽管所有的努力,目前没有有效的治疗方法来防止恶病质患者的肌肉萎缩。
一个多学科的研究团队,在药物输送、基因治疗和癌症方面具有互补的专业知识。
恶病质将开发出恶病质相关的肌肉消耗的有效治疗。它将基于
聚合物纳米颗粒,其被专门设计用于在施用后将卵泡抑素信使RNA(mRNA)递送至肝细胞,
系统管理。递送的mRNA将指导肝细胞的细胞机器产生
卵泡抑素,一种分泌的糖蛋白,能够通过抑制肌肉生长抑制素增加瘦肌肉质量
激活素A。最后两种是生长分化因子,其血清浓度在哺乳动物中增加。
恶病质状态,它们在负调节肌肉质量中起着关键作用。
该研究小组已经开发出了无毒并提高血清的mRNA负载纳米平台
皮下注射后8 h内卵泡抑素蛋白水平。野生型小鼠,
纳米平台表现出瘦体重的显著增加。为了进一步推进这项技术,目标
(i)增强已经开发的纳米颗粒向肝脏的递送,(ii)评估递送
(iii)验证纳米颗粒在具有人源化肝脏的小鼠中的治疗功效,
在新型鼠胰腺导管腺癌(PDAC)和肺癌模型中,
人类恶病质的标志性特征这些目标将通过以下具体目标来实现:1
评价静脉内给药后装载mRNA的纳米颗粒的有效性。2.测试纳米平台
人类化肝脏的小鼠。3.确定纳米颗粒介导的卵泡抑素mRNA的递送
减轻PDAC和肺癌小鼠模型中的恶病质。
在这个项目完成后,研究小组将提出强有力的证据,证明所提出的治疗将
在胰腺癌和肺癌小鼠中保留肌肉质量并减轻恶病质的其他特征。的
该项目的长期影响是在医疗实践中成功应用新疗法,
足以限制死亡和罹患各种癌症,包括肺癌和胰腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Oleh Taratula其他文献
Oleh Taratula的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Oleh Taratula', 18)}}的其他基金
Intravascular Delivery of Nanoclusters for Treatment of Deep-Seated Cancers with Magnetic Hyperthermia
血管内输送纳米簇用于磁热疗治疗深部癌症
- 批准号:
9887348 - 财政年份:2020
- 资助金额:
$ 44.64万 - 项目类别:
Intravascular Delivery of Nanoclusters for Treatment of Deep-Seated Cancers with Magnetic Hyperthermia
血管内输送纳米簇用于磁热疗治疗深部癌症
- 批准号:
10350590 - 财政年份:2020
- 资助金额:
$ 44.64万 - 项目类别:
Intravascular Delivery of Nanoclusters for Treatment of Deep-Seated Cancers with Magnetic Hyperthermia
血管内输送纳米簇用于磁热疗治疗深部癌症
- 批准号:
10115664 - 财政年份:2020
- 资助金额:
$ 44.64万 - 项目类别:
Intravascular Delivery of Nanoclusters for Treatment of Deep-Seated Cancers with Magnetic Hyperthermia
血管内输送纳米簇用于磁热疗治疗深部癌症
- 批准号:
10555274 - 财政年份:2020
- 资助金额:
$ 44.64万 - 项目类别:
Novel Nanomedicine-Based Therapeutic Approach For Treatment of Cancer Cachexia
治疗癌症恶病质的新型纳米医学治疗方法
- 批准号:
10602425 - 财政年份:2019
- 资助金额:
$ 44.64万 - 项目类别:
Novel Nanomedicine-Based Therapeutic Approach For Treatment of Cancer Cachexia
治疗癌症恶病质的新型纳米医学治疗方法
- 批准号:
9923595 - 财政年份:2019
- 资助金额:
$ 44.64万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 44.64万 - 项目类别:
Research Grant